A multicenter, open-label, single-arm, Phase 4 clinical study to evaluate the pharmacokinetics, efficacy, and safety of belumosudil mesylate tablets in Chinese adolescents (aged from 12 to less than 18 years) with chronic graft-versus-host disease (cGVHD) who have had an inadequate response to glucocorticoids or other systemic therapies

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2026
This article has no abstract
Epistemonikos ID: cc16d4e63be54d921850009ab88cab5836d1de04
First added on: Oct 09, 2026